Immunotherapy Approvals by the FDA

I wanted to repost this list of FDA approvals of immunotherapeutics that blogger, Brad Loncar has published (***). I made a word cloud of his results and, as expected, Keytruda (pembrolizumab) and Opivid (nivolumab) had the greatest hits for therapies. In recent years the PD-1 inhibitor, Keytruda, has galvanized the immunotherapy field. Keytruda has been found to show indications in advanced non-small cell lung cancer, advanced melanoma, head and neck squamous cell carcinoma, Hodgkin lymphoma, and advanced urothelia bladder cancer. Hopefully, more malignancies can be targeted by Keytruda, along with other drugs.